

Prevalence of AmpC and Extended-Spectrum Beta-Lactamase Producing *E. coli* and *Klebsiella spp.* in Sewage Effluents of Dharan, Nepal

Prashant Dahal^{1*}, Rojina Rai², Madhav Raj Sharma³, Lalit Narayan Chaudhary⁴, Prabha Nand Chaudhary⁵, Mausham Poudel⁶, Niku Khadka⁷, Rabin Rai⁸

*Department of Microbiology, Sunsari Technical College, Dharan, Province-1, Nepal

RESEARCH ARTICLE

ABSTRACT

Background: The prevalence of extended-spectrum β -lactamase (ESBL) and AmpC β -lactamase (ABL) producing Enterobacteriaceae is increasing rapidly across the world. Members of *Enterobacteriaceae* like *E. coli* and *Klebsiella spp.* exhibit antimicrobial resistance mainly due to the production of beta-lactamase enzymes like extended-spectrum β -lactamases, AmpC β -lactamases, and carbapenemases. These bacteria are frequently reported in sewage effluents of hospital and municipal sewerage systems indicating sewage as a promising source for dissemination of such drug-resistant pathogens. However, in most of the developing countries including Nepal, the major portion of sewage is discharged in water sources without proper treatment and disinfection. This study was undertaken to assess the prevalence of ESBL and ABL producing *E. coli* and *Klebsiella spp.* in sewage effluents of Dharan, Nepal.

Results: A total of 235 bacteria were isolated, out of which 103 (43.83 %) were *E. coli* and 132 (56.17 %) were *Klebsiella spp.* ESBL production was seen in 157 (66.81 %) isolates. Among them, 89 (56.69 %) were *Klebsiella spp.* and 68 (43.31 %) were *E. coli*. 66.02 % of total isolated *E. coli* and 67.42 % of total isolated *Klebsiella spp.* showed production of ESBL enzymes. ABL production was seen in 133 (56.59 %) isolates. Among them, 54 (40.60 %) were *E. coli* and 79 (59.40 %) were *Klebsiella spp.* 52.43 % of the isolated *E. coli* and 59.85 % of isolated *Klebsiella spp.* were found producing ABL enzyme.

Conclusions: The results indicate that there is a high prevalence of ESBL and ABL producing *E. coli* and *Klebsiella spp.* in sewage effluents of Dharan. Effective treatment of sewage effluents must be ensured before discharging the sewage into the environment. National guidelines for discharging the municipal sewage must be immediately amended and an effective treatment system before discharge must be implemented. Dissemination of such drug-resistant bacteria in the human population leading to severe public health emergency is likely to occur from sewage contamination, so further study and surveillance and effective prevention and control measures are necessary.

KEYWORDS

ESBL, ABL, *Enterobacteriaceae*, *E. coli*, *Klebsiella spp.*, Sewage effluent

Correspondence to: Dr. Prashant Dahal, Department of Microbiology, Sunsari Technical College, Dharan, Province-1, Nepal, Email: dahalprashant097@gmail.com

Received: November 20, 2023, **Accepted:** November 27, 2023, **Published:** December 06, 2023

DOI: 10.1042/JCTCS.6.1.009

Citation: Prashant Dahal, 2023, Prevalence of AmpC and Extended-Spectrum Beta-Lactamase Producing *E. coli* and *Klebsiella spp.* in Sewage Effluents of Dharan, Nepal, JCTCS. Vol 6.

Copyright: © 2023, Prashant Dahal, All intellectual property rights, including copyrights, trademarks rights and database rights with respect to the information, texts, images, logos, photographs and illustrations on the website and with respect to the layout and design of the website are protected by intellectual property rights and belong to Probe Publisher or entitled third parties. The reproduction or making available in any way or form of the contents of the website without prior written consent from Probe Publisher is not allowed.

BACKGROUND

Sewage is the collection of wastewater in a municipal pipe system or sewerage channel. It is mostly a combination of domestic effluents from toilets, bathing, and kitchen, water from commercial establishments and institutions including hospitals and clinics, hotels and restaurants, shops and markets, schools, colleges, and different offices, industrial effluents, and surface runoff water [1]. Sewage water contains a different variety of organic and inorganic wastes and nutrients merged from different sources. Hospital sewage water is loaded with several pathogenic microorganisms with antimicrobial resistance capacity, partially metabolized pharmaceutical substances like antimicrobial, pharmaceutical, disinfectants, and un-metabolized

drugs, radioactive elements, and other toxic substances. Non-hospital sewage is loaded with microorganisms from human and animal feces and environmental sources. This will make sewage more prone to pathogenic organisms including antibiotic-resistant bacteria [2]. Different studies have shown the presence of antibiotic-resistant bacteria and genes which have even escaped treatment systems and disseminated in [3]. Wastewater treatment systems can reduce contaminants including microorganisms to a minimum limit, but only 5 % of generated wastewater is treated appropriately while the remaining is directly connected to water bodies in Nepal. This has resulted in the transmission of microorganisms and water-borne infections [4].

Enterobacteriaceae covers a large part of hospital sewage microbiota [5]. Among the sewage pathogens, coliforms are responsible for frequent human infections [6]. Coliforms are aerobic or facultative, Gram-negative, non-sporing lactose fermenting bacteria. They were traditionally represented by 4 genera viz. *Escherichia*, *Klebsiella*, *Citrobacter*, and *Enterobacter*, but now contain over 20 bacterial genera [7]. *Enterobacteriaceae* includes different Gram-negative bacteria including pathogenic genera like *Escherichia*, *Salmonella*, *Shigella*, *Klebsiella*, and *Serratia* [8]. *Klebsiella pneumoniae* and *E. coli* of *Enterobacteriaceae* have notable antibiotic resistance to a wide variety of antibiotics typically used in the treatment of their infection [8-10].

Members of *Enterobacteriaceae* like *E. coli* and *Klebsiella spp.* exhibit antimicrobial resistance mainly due to the production of beta-lactamase enzymes like extended-spectrum β -lactamases, AmpC β -lactamases, and carbapenemases [11]. *Enterobacteriaceae* were found to produce intrinsic chromosomal encoded beta-lactamases but due to the transfer of such gene to transferable plasmid gene, there is rapid dissemination of *Enterobacteriaceae* resistant to a wide variety of beta-lactam antibiotics [12]. ESBLs are β -lactamases capable of developing resistance against β -lactam drugs like penicillins, extended-spectrum cephalosporins, and monobactams except for cephamycins and carbapenems and susceptible to β -lactam inhibitor clavulanic acid [13]. ABL is characterized by the hydrolysis of broad-spectrum cephalosporins like cefotaxime and ceftazidime and cephamycins (7- α -methoxy cephalosporins) like cefoxitin and cefotetan, including monobactam, and the β -lactam/ β -lactam inhibitor combination, but are sensitive to cefepime and carbapenems [14].

Different clinical isolates of *E. coli* and *Klebsiella spp.* are found to be antibiotic resistant and produce ESBL and ABL enzymes for conferring the resistance against β -lactam antibiotics. [15] Concluded on the higher prevalence of ESBL producing *E. coli* and *Klebsiella spp.* in Nepal by examining 2209 non-repetitive MSU samples at a tertiary hospital of Nepal. Similarly, [16, 17] concluded the high prevalence of ABL producers in clinical isolates. [2] Studied sewage effluents of different hospitals of Biratnagar, Nepal, and concluded the prevalence of MDR and ESBL producing *E. coli* and *Klebsiella spp.* in hospital sewage effluents.

Sewage effluents have high potentiality as an environmental reservoir of a wide variety of pathogenic organisms including ESBL and ABL producing *E. coli* and *Klebsiella spp.* unfortunately, scanty research is done on sewage effluents as a source of such pathogens. The present study was undertaken to reduce the research gap on assessment of sewage microbiota with the sole focus on determining the prevalence of ESBL and ABL producing *E. coli* and *Klebsiella spp.* in sewage effluents of Dharan, Nepal.

RESULTS

Distribution of *E. coli* and *Klebsiella spp.* in the Samples

Among the total of 20 samples analyzed 16 samples (80 %) showed growth of either *E. coli* or *Klebsiella spp.* or both and 4 samples (20 %) did not show growth of *E. coli* and *Klebsiella spp.* (Table 1). Out of 16 positive samples, 13 (81.25 %) showed growth of both *E. coli* and *Klebsiella spp.*, 2 (12.5 %) showed growth of *Klebsiella spp.* only and 1 (6.25 %) showed growth of *E. coli* only. All of the hospital-sewage effluents (6 out of 6) and 8 of the non-hospital sewage effluents (8 out of 14) showed growth of both *E. coli* and *Klebsiella spp.* (Table 1). This showed that 70 % of the samples contained *E. coli* and 75 % of the samples contained *Klebsiella spp.*

Sample	Location	Bacteria Isolated	
		<i>E. coli</i>	<i>Klebsiella spp.</i>
1	BPKIHS, Dharan	+	+
2	BPKIHS, Dharan	+	+
3	BPKIHS, Dharan	+	+
4	BPKIHS, Dharan	+	+
5	Bijaypur Hospital Pvt.Ltd	+	+
6	Bijaypur Hospital Pvt. Ltd	+	+
7	Residential area – 1	-	-

8	Residential area – 2	+	+
9	Residential area – 3	-	+
10	Residential area – 4	-	-
11	Market area – 1	+	+
12	Market area – 2	+	+
13	Market area – 3	+	+
14	Commercial area – 1	+	+
15	Commercial area – 2	+	+
16	Commercial area – 3	+	-
17	Commercial area – 4	-	-
18	Commercial area – 5	-	+
19	Commercial area – 6	-	-
20	Commercial area – 7	+	+

Table 1: Prevalence of *E. coli* and *Klebsiella spp.* in each sample.

A total of 235 bacteria were identified as either *E. coli* or *Klebsiella spp.* Out of them, 103 isolates (43.83 %) were *E. coli* and 132 isolates (56.17 %) were *Klebsiella spp.* The prevalence of *Klebsiella* was found to be higher. (Figure 1)




Figure 1: Proportion of isolated *E. coli* and *Klebsiella spp.*

Antibiotic Susceptibility Pattern of Isolated *E. coli* and *Klebsiella spp.*

Antibiotic sensitivity test of selected antibiotics against the isolated *E. coli* and *Klebsiella spp.* showed the highest sensitivity to Azithromycin (63.82 %) and the lowest sensitivity to Cefoxitin (1.28 %) (Table 2).

Antibiotics	Disc Content (in µg)	Susceptibility Pattern	
		Sensitive n (%)	Resistant n (%)
Ampicillin	10	27 (11.49 %)	208 (88.51 %)
Azithromycin	15	150 (63.83 %)	85 (36.17 %)
Aztreonam	30	55 (23.40 %)	180 (76.60 %)
Ciprofloxacin	5	113 (48.09 %)	122 (51.91 %)
Co-Trimoxazole	25	146 (62.13 %)	89 (37.87 %)

Ceftriaxone	30	45 (19.15 %)	190 (80.85 %)
Ceftazidime	30	39 (16.59 %)	196 (83.41 %)
Cefotaxime	30	41 (17.45 %)	194(82.55 %)
Cefoxitin	30	3 (1.28 %)	232 (98.72 %)
Imipenem	10	140 (59.57 %)	95 (40.43 %)
Nitrofurantoin	300	127 (54.04 %)	108 (45.96 %)

Table 2: Antibiotic Susceptibility Pattern of Isolated *E. coli* and *Klebsiella spp.*

Beta-lactam antibiotics; Ampicillin, Aztreonam, Ceftriaxone, Ceftazidime, Cefotaxime, and Cefoxitin showed very poor sensitivity patterns showing the sensitive result to only 11.49 %, 23.40 %, 19.15 %, 16.59 %, 17.45 %, and 1.28 % of tested bacteria respectively. Ciprofloxacin showed sensitivity to 48.09 % of the tested bacterial species, while Co-Trimoxazole showed sensitivity to 62.13 % of the tested bacterial species. Imipenem showed a sensitive result on 59.57 % of the tested bacteria. Nitrofurantoin showed a sensitive result on 54.04 % of the tested bacteria.

Antibiotic susceptibility test of *E. coli* revealed that 84.47 % of them were sensitive to Nitrofurantoin, while only 2.91 % were sensitive to Cefoxitin. Ampicillin, Azithromycin, Aztreonam, Ciprofloxacin, Co-Trimoxazole, Ceftriaxone, Ceftazidime, Cefotaxime, and Imipenem showed sensitivity against 15.53 %, 55.34 %, 31.07 %, 48.54 %, 68.93 %, 31.07 %, 25.24 %, 20.39 %, and 58.25 % of the tested *E. coli* respectively.

On other hand, 70.45 % of *Klebsiella spp.* were sensitive to Azithromycin and 0 % of *Klebsiella spp.* were sensitive to Cefoxitin. Ampicillin, Aztreonam, Ciprofloxacin, Co-Trimoxazole, Ceftriaxone, Ceftazidime, Cefotaxime, Imipenem, and Nitrofurantoin showed sensitivity against 8.33 %, 17.42 %, 47.73 %, 56.82 %, 9.8B5 %, 9.85 %, 15.15 %, 60.61 %, and 30.31 % of the tested *Klebsiella spp.* respectively.

Distribution of ABL Producing *E. coli* and *Klebsiella spp.*

133 isolates (56.59 %) were found positive for ABL production. Among 133, 54 (40.60 %) were *E. coli* and 79 (59.40 %) were *Klebsiella spp.* (Figure 2) This showed a higher prevalence of ABL producing *Klebsiella spp.* than *E. coli* in sewage effluents of Dharan.




Figure 2: Distribution of ABL Producing *E. coli* and *Klebsiella spp.*

Distribution of ESBL Producing *E. coli* and *Klebsiella spp.*

ESBL production was seen in 157 isolates (66.81 %) while testing 235 isolated bacteria. Out of 157 ESBL producing 89 (56.69 %) were *Klebsiella spp.* and 68 (43.31 %) were *E. coli*. (Figure 3) This showed a higher prevalence of ESBL producing *Klebsiella spp.* than *E. coli* in sewage effluent of Dharan.




Figure 3: Distribution of ESBL Producing *E. coli* and *Klebsiella spp.*

Distribution of ABL and ESBL Co-producing *E. coli* and *Klebsiella spp.*

A total of 118 isolates showed the production of both ABL and ESBL enzymes. This accounted for 50.21 % of total isolated bacteria. Out of 118 co-producers, 51 (43.22 %) were *E. coli*, and the remaining 67 (56.78 %) were *Klebsiella spp.* (Figure 4) Prevalence of ABL and ESBL co-production was comparatively higher in *Klebsiella spp.* than in *E. coli*.




Figure 4: Distribution of ABL and ESBL Co-producing *E. coli* and *Klebsiella spp.*

DISCUSSION

Beta-lactam antibiotics are among the most widely used antibiotic class [18]. Bacteria have developed resistance to β -lactam antibiotics by evolving their ability to synthesize several types of β -lactamase enzymes capable of hydrolyzing β -lactam ring. Among the β -lactamase enzymes ESBL and ABL are the most commonly encountered types [19, 20]. Resistance to β -lactam antibiotics by producing ESBL and ABL enzymes is increasing rapidly among members of *Enterobacteriaceae* across the world [21, 22]. This study was conducted to detect the prevalence of ABL and ESBL producing *E. coli* and *Klebsiella spp.* in sewage effluents of Dharan. A total of 20 samples were analyzed in the Molecular and Microbiology Laboratory of Sunsari Technical College, Dharan-1 from May 21, 2021, to October 29, 2021. The phenotypic method was used to confirm the production of AmpC Beta-lactamase and Extended Spectrum Beta-lactamase enzymes in the isolated species using the methods recommended by CLSI (Patel & [23])

Among the total of 20 samples analyzed 16 samples (80 %) showed growth of either *E. coli* or *Klebsiella spp.* or both and 4 samples (20 %) did not show growth of *E. coli* and *Klebsiella spp.* Among the studied sample, 70 % (14 out of 20) showed the presence of *E. coli*, and 75 % (15 out of 20)

showed the presence of *Klebsiella spp.* Mahato et al., 2019 had reported that 70 % of sewage effluents contained *E. coli* while only 60 % of the sewage effluents contained *Klebsiella spp.* This variation may be since Mahato et al., 2019 had studied hospital sewage effluents only while we studied both hospital and municipal sewage.

In the study, 235 bacteria were identified as either *E. coli* or *Klebsiella spp.* 103 (43.83 %) of them were *E. coli*, whereas 132 (56.17 %) of them were *Klebsiella spp.* Results obtained by Mahato et al., 2019 were different. They had shown that 53.85 % of their isolates were *E. coli*, while 46.15 % were *Klebsiella spp.* Had shown that 65.71 % of their isolates were *Klebsiella spp.* and only 10 % were *E. coli*.

Ampicillin resistance was seen in 84.47 % of *E. coli*. It was 44.66 % for Azithromycin, 68.93 % for Aztreonam, 51.46 % for Ciprofloxacin, 31.07 % for Co-Trimoxazole, 68.93 % for Ceftriaxone, 74.76 % for Ceftazidime, 79.61 % for Cefotaxime, 97.09 % for Cefoxitin, 41.75 % for Imipenem, and 15.53 % for Nitrofurantoin. This result was similar to Mahato et al., 2019 for Ampicillin, Aztreonam, and Cefoxitin. They had shown 100 % resistance to these antibiotics. But, for Co-Trimoxazole, Ceftazidime, Ceftriaxone, and Cefotaxime they had shown resistance to 85.7 % which was higher than the result obtained in this research. Similarly, they had shown that resistance to Nitrofurantoin was 42.9 %, which was higher in comparison to this research. For Azithromycin, they had shown that non-of them (0 %) were resistant, but 44.66 % were found resistant in this research. They had reported that 14.3 % were found to be resistant to Ciprofloxacin but it was 51.46 % in this research.

This study showed that 91.67 % of *Klebsiella spp.* were resistant to Ampicillin. It was 29.55 % for Azithromycin, 82.58 % for Aztreonam, 52.27 % for Ciprofloxacin, 43.18 % for Co-Trimoxazole, 90.15 % for Ceftriaxone, 90.15 % for Ceftazidime, 84.85 % for Cefotaxime, 100 % for Cefoxitin, 39.39 % for Imipenem, and 69.69 % for Nitrofurantoin. The result was shown by Mahato et al., 2019 indicates comparatively higher resistance against Ampicillin and Co-Trimoxazole, and lower to the other antibiotics.

ESBL production was found higher in *Klebsiella spp.* than in *E. coli*. Out of 157 ESBL producers, 43.31 % (68) were *E. coli* and 56.69 % (89) were *Klebsiella spp.* Mahato et al., 2019 showed higher ESBL production in *E. coli* (66.67 %) than in *Klebsiella spp.* (33.33 %). Similarly, Zaatout et al., 2021 also had reported a higher prevalence of ESBL *E. coli* in sewage effluents than that of *Klebsiella spp.* Fadare & Okoh, 2021 on the other hand had shown a higher prevalence of ESBL producing *Klebsiella spp.* than *E. coli* in hospital wastewater. ESBL production was seen in 81.59 % of total tested *E. coli* and 85.61 % of total tested *Klebsiella spp.* A higher prevalence of ESBL producing *E. coli* was found by (Reinthal et al., 2009 [24, 25]).

ABL production was also found to be higher in *Klebsiella spp.* than in *E. coli*. Among 133 ABL producers, 59.40 % (79) were *Klebsiella spp.* and 40.60 % (54) were *E. coli*. Among 57 wastewater samples tested by [26] 24 were found to be positive for ESBL-Eb or pAmpC-Eb producing *Enterobacteriaceae*. They detected ESBL-Eb in 20 samples, and pAmpC-Eb in 4 samples. No relevant literature on ABL producing *E. coli* and *Klebsiella spp.* in sewage effluents were found for further comparison.

ESBL and ABL co-production was seen in 50.21 % (total 118) of the isolates. 75 % of the ESBL producing *E. coli* were found to produce ABL also, and 75.28 % of the ESBL producing *Klebsiella spp.* were found to produce ABL also. This result was higher than that of Rizi et al., 2020. They had shown co-production in only 30 % of the isolated *E. coli* and *Klebsiella spp.* Similarly, co-production was seen in 29 % of the isolated *E. coli* and *Klebsiella pneumoniae* in research by (Hertz et al., 2019 [27]). Co-production was seen in 9.38 % of isolated *E. coli* and non (0 %) of isolated *Klebsiella spp.* by (Shrestha et al., 2019 [28]). These variations may be because all these studies are on clinical isolates.

CONCLUSION

Based on the finding of the present study, it can be concluded that sewage effluents of Dharan have a higher prevalence of ESBL and ABL producing *E. coli* and *Klebsiella spp.* This suggests that there may be a direct link between human or animal feces in the sewage system. The result is an alarming indicator of a probable outbreak of life-threatening infection by β -lactamase producing *E. coli* and *Klebsiella spp.* if sewage is contaminated with drinking water channels or food in the Dharan area. There is an urgent need for further research in sewage microflora and the probability of their dissemination to human populations. Government bodies should prepare effective regulatory measures to control the irrational use of antibiotics and monitor the antimicrobial resistance status of different suspected bacteria. Effective alternatives for the treatment of ESBL and ABL producing *E. coli* and *Klebsiella spp.* may be needed soon. Immediate and effective response from concerned authorities for controlling the dissemination of such bacteria from sewage to the environment or community is required. Regular monitoring and study of antibiotic susceptibility patterns of several bacteria in different aspects of the environment like sewage is needed.

METHODS

Design and Setting of Study

A laboratory-based cross-sectional quantitative study was designed. The study was conducted in Dharan sub-metropolitan city. It is a city in Koshi zone's Sunsari district of Province-1, Nepal with co-ordinates 26°49'0"N 87°17'0"E. The study was conducted from May 21, 2021, to October 29, 2021. Sewage effluents, directly from the municipal sewage channel, were taken as samples for the study. Non-probability convenience sampling method was followed for sample collection.

Sample Collection and Transportation

A total of 20 samples were taken from different sites of Dharan city. Samples were taken considering that it would cover almost every part of the city. Out of 20 samples, 6 samples (30 %) were from the hospital area, and the remaining 14 samples (70 %) were from the non-hospital area.

Samples were collected directly from the center of the sewage flow channel. For hospital sewages, samples were collected from the point where hospital sewage is connected to the municipal sewerage channel. A pre-sterilized sterile glass bottle was used to collect the sample from the flow channel with the help of a sampling rod. About 100 mL of sewage effluents were taken from one site. Each bottle was labeled with the date, sample location, and time of collection. Collected samples were transported to the laboratory immediately maintaining a cold chain in the ice-box to inhibit the growth of microorganisms. [2]

Sample Processing and Inoculation

Samples were serially diluted in sterilized distilled water (SDW) up to tenfold. Eosin-methylene blue (EMB) agar plates and MacConkey (MAC) agar plates were prepared and solidified properly about 3-4 hours before inoculation. 5 plates of each media were prepared and labeled as E10⁻², E10⁻⁴, E10⁻⁵, E10⁻⁶, and Econtrol on EMB plates and M10⁻², M10⁻⁴, M10⁻⁵, M10⁻⁶, and Mcontrol for MAC plates. From the serially diluted samples in the tube, 100 µL of the sample was pipetted out after mixing properly and inoculated on the agar plates using the spread-plate (lawn culture) method. Dilution 10⁻², 10⁻⁴, 10⁻⁵, and 10⁻⁶ were inoculated. The plates were incubated aerobically at 37°C for 24 hours.

Isolation and Identification of *E. coli* and *Klebsiella spp.*

Following incubation colonies were isolated from the plate with well-isolated colonies. MAC was used for isolation of *Klebsiella spp.* and EMB was used for isolation of *E. coli*. [2]. From MAC plates, well-isolated colonies which were showing characters of *Klebsiella spp.* were marked and streaked on Nutrient Agar (NA) plates for purification. Similarly, well-isolated colonies which were showing characters of *E. coli* in EMB plates were marked and isolated in NA plates [27].

The isolated pure colonies on NA plates were Gram-stained and observe under a microscope for morphological characterization. After Gram staining, biochemical tests were performed. IMViC test, catalase test, oxidase test, motility test, H₂S production test, and TSI test were performed to confirm the identification of isolates as *E. coli* and *Klebsiella spp* [28, 29]

Antimicrobial Susceptibility Testing

Antimicrobial susceptibility tests of the isolates were performed by Kirby-Bauer disc diffusion method on Muller Hilton Agar (Hi-Media, India) according to CLSI 2017 guidelines (Patel & Clinical and [23]). Amoxicillin (10 µg), Aztreonam (30 µg), Azithromycin (15 µg), Ciprofloxacin (5 µg), Co-Trimoxazole (25 µg), Cefoxitin (30 µg), Ceftazidime (30 µg), Ceftriaxone (30 µg), Cefotaxime (30 µg), Imipenem (10 µg), and Nitrofurantoin (300 µg) were used for the AST. Following incubation, zone size was measured and compared with the AST chart provided by CLSI for *E. coli* and *Klebsiella spp.* for the tested antibiotic discs. All the isolated *E. coli* and *Klebsiella spp.* were tested for the production of ESBL and ABL enzymes.

Phenotypic Confirmation of ESBL Production

The combination disc method was used to phenotypically confirm the ESBL production by the isolated *E. coli* and *Klebsiella spp.* Two combination discs, Cefotaxime (CTX) 30µg vs. Cefotaxime + Clavulanic acid (CEC) 30/10 µg, and Ceftazidime (CAZ) 30 µg vs. Ceftazidime + Clavulanic acid (CAC) 30/10 µg were used.

Those isolated *E. coli* and *Klebsiella* strains which showed an increase in zone size by ≥5 mm in combination discs (CAC and CEC) than those of CTX and CAZ discs alone were confirmed as ESBL producers [30].

Phenotypic Confirmation of ABL Production

The combination disc method was used for phenotypic confirmation of ABL production among isolated *E. coli* and *Klebsiella spp.* Combination disc Cefoxitin (CX) 30 µg vs. Cefoxitin + Cloxacillin (CC) 30/200 µg was used. Those isolated *E. coli* and *Klebsiella* strains which showed an increase in zone size by ≥4 mm in combination discs CC than that of CX alone was confirmed as ABL producers [31, 32].

Journal of Clinical Trials and Case Studies

List of Abbreviations

ESBL –	Extended Spectrum Beta-Lactamase
ABL –	AmpC Beta-Lactamase
BPKIHS-	BP Koirala Institute of Health Science
MSU –	Mid Stream Urine
MDR –	Multi Drug-Resistant
CLSI –	Clinical and Laboratory Standards Institute
ESBL - Eb-	Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae
pAmpC-Eb-	Plasmid Mediated AmpC Producing Enterobacteriaceae
SDW -	Sterile Distilled Water
MAC-	MacConkey
EMB-	Eosin Methylene Blue
CTX-	Cefotaxime
CEC-	Cefotaxime + Clavulanic acid
CAZ-	Ceftazidime
CAC-	Ceftazidime + Clavulanic acid
CX-	Cefoxitin
CC-	Cefoxitin + Cloxacillin

DECLARATIONS

Ethical Approval and Consent to Participate

Not applicable

Consent for Publication

Not applicable

Availability of Data and Materials

The datasets supporting the conclusion of this article are included within the article. The raw data will be available from the corresponding author on a reasonable request.

Competing Interests

The authors declare that they have no competing interests

FUNDING

Self-funded

AUTHOR'S CONTRIBUTION

PD and RR conceived the topic and designed the proposal. PD, RR, and MRS prepared the conceptual framework and methodology for experiments. LNC, PNC, PD, and MP performed the field works and experiments. RR and NK managed and analyzed the data. RR and PD wrote the paper. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

We would like to express our sincere gratitude to Mr. Sagar Aryal for his technical support, guidance, and manuscript editing.

REFERENCES

- 1) Mateo-Sagasta J, Raschid-Sally L, Thebo A. Global Wastewater and Sludge Production, Treatment and Use. In P. Drechsel, M. Qadir, & D. Wichelns (Eds.), *Wastewater*. 2015, 1:15-38.
- 2) Mahato S, Mahato A, Pokharel E, Tamrakar A. Detection of extended-spectrum beta-lactamase-producing *E. coli* and *Klebsiella* spp. In effluents of different hospitals sewage in Biratnagar, Nepal. *BMC Res Notes*. 2019, 12:641.
- 3) Nasser AM, Fawaqa H, Nitzan Y. The role of wastewater treatment plants in the environmental dissemination of Antibiotic Resistant Bacteria (ARB) and Resistance Genes (ARG). *J Water Resour Protec*. 2019, 11:981-994.
- 4) Jha AK, Bajracharya TR. *Wastewater treatment technologies in Nepal*. 2014, 7:76-81.
- 5) Korzeniewska E, Harnisz M. Beta-lactamase-producing Enterobacteriaceae in hospital effluents. *J Environ Manage*. 2013, 123:1-7.
- 6) Doi Y, Iovleva A, Bonomo RA. The ecology of extended-spectrum β -lactamases (ESBLs) in the developed world. *J Travel Med*. 2017, 24:S44-51.
- 7) Masiello SN, Martin NH, Trmčić A, Wiedmann, M, Boor KJ. Identification and characterization of psychrotolerant coliform bacteria isolated from pasteurized fluid milk. *J Dairy Sci*. 2016, 99:130-140.
- 8) Rock C, Donnenberg MS. Human pathogenic Enterobacteriaceae. In Reference Module in Biomedical Sciences. Elsevier.
- 9) Le TH, Ng C, Chen H, Yi XZ, Koh, TH., et al Occurrences and characterization of antibiotic-resistant bacteria and genetic determinants of hospital wastewater in a tropical country. *J Antimicrob Chemoth*. 2016, 60:7449-7456.
- 10) Kazemian H, Heidari H, Ghanavati R, Ghafourian S, Yazdani F, et al. Phenotypic and genotypic characterization of ESBL-, AmpC-, and Carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* isolates. *Med Princ Pract*. 2019, 28:547-551.
- 11) Ojer-Usoz E, González D, Vitas AI, Leiva J, García-Jalón I, et al. Prevalence of extended-spectrum β -lactamase-producing Enterobacteriaceae in meat products sold in Navarra, Spain. *Meat Sci*. 2013, 93:316-321.
- 12) Susić E. Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics. *Acta Medica Croatica: Casopis Hrvatske Akademije Medicinskih Znanosti*. 2004, 58:307-312.
- 13) Raut S, Gokhale S, Adhikari B. Prevalence of extended spectrum Beta-Lactamases among *Escherichia coli* and *Klebsiella* spp isolates in Manipal Teaching Hospital, Pokhara, Nepal. *J Microbiol Infect Dis*. 2015, 5:69-75.
- 14) Dehkharghani AD, Haghghat S, Farzami MR, Rahbar M. The mechanism of resistance in AmpC-producing *Escherichia coli* isolated from urinary tract infections. *Arch Med Lab Sci*. 2020, 6:1-9.
- 15) Shakya P, Shrestha D, Ma an E, Sharma VK, Paudyal R. ESBL Production among *E. coli* and *Klebsiella* spp. Causing urinary tract infection: A hospital based study. *Open Microbiol J*. 2017, 11:23-30.
- 16) Baral P, Neupane S, Shrestha B, Ghimire, KR, Marasini BP et al. Clinical and microbiological observational study on AmpC β -lactamase-producing Enterobacteriaceae in a hospital of Nepal. *Braz J Infect Dis*. 2013, 17:256-259.
- 17) Aryal SC, Upreti MK, Sah AK, Ansari M, Nepal K, et al. Plasmid-Mediated AmpC β -Lactamase CITM and DHAM genes among gram-negative clinical isolates. *Infect Drug Resist*. 2020, 13:4249-4261.
- 18) Bush K, Bradford PA. β -Lactams and β -Lactamase inhibitors: An overview. *CSH Perspect Med*. 2016, 6:a025247.
- 19) Bush K, Bradford PA. Epidemiology of β -Lactamase-Producing Pathogens. *Clin Microbiol Rev*. 2020, 33.
- 20) Bush K, Jacoby GA. Updated functional classification of β -Lactamases. *Antimicrob Agents CH*. 2010, 54:969-976.
- 21) Caron Y, Chheang R, Puthea N, Soda M, Boyer S, et al. Beta-lactam resistance among Enterobacteriaceae in Cambodia: The four-year itch. *Int Infect Dis*. 2018, 66:74-79.
- 22) De Angelis G, Del Giacomo P, Posteraro B, Sanguinetti M, Tumbarello M. Molecular mechanisms, epidemiology, and clinical importance of β -lactam resistance in enterobacteriaceae. *Int J Molec Sci*. 2020, 21:5090.
- 23) Patel JB. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute. 2017.
- 24) Fadare FT, Okoh AI. Distribution and molecular characterization of ESBL, pAmpC β -lactamases, and non- β -lactam encoding genes in Enterobacteriaceae isolated from hospital wastewater in Eastern Cape Province, South Africa. 2021, 16:e0254753.
- 25) Reinthaler F, Feierl G, Galler H, Haas D, Leitner E, et al. ESBL-producing *E. coli* in Austrian sewage sludge. *Water Res*. 2009, 44:1981-1985.
- 26) Said BL, Jouini A, Alonso CA, Klibi N, Dziri R, et al. Characteristics of extended-spectrum β -lactamase (ESBL) - and pAmpC beta-lactamase-producing Enterobacteriaceae of water samples in Tunisia. *Sci Total Environ*. 2016, 550:1103-1109.
- 27) Anderson DG, Salm SN, Allen D, Nester EW, Nester EW (Eds). *Nester's microbiology: A human perspective (Ninth edition)*. McGraw-Hill Education. 2019.

- 28) Shrestha B, Acharya J, Chhetri J, Gurung K, Rai KM. Distribution of extended Spectrum β -Lactamase and AMPC- β Lactamase among bacteria Isolated from urine samples. *J Heal Allied Sci.* 2019, 5:21-24.
- 29) Rosa B, Victor T, Vivas-reyes R, Montes A, Arzuza O. Anti-biofilm activity of ibuprofen and diclofenac against some biofilm producing *Escherichia coli* and *Klebsiella pneumoniae* uropathogens. *Afr J Microbiol Res.* 2016, 10:1675-1684.
- 30) Paterson DL, Bonomo RA. Extended-Spectrum β -Lactamases: A clinical update. *Clin Microbiol Rev.* 2005, 18:657-686.
- 31) Pölsfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, et al. Practical approach for reliable detection of AmpC Beta-Lactamase-producing Enterobacteriaceae. *J Clin Microbiol.* 2011, 49:2798-2803.
- 32) Hertz F, Jansåker F, Okon K, Sulaiman A, Onah J, et al. ESBL-production in *Escherichia coli* and *Klebsiella pneumoniae* isolates from Nigeria. *Microbiol Open.* 2019,8:e00816.